Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-23T13:42:50.506Z Has data issue: false hasContentIssue false
  • English
  • Français

Heart rate variability in β-thalassaemia major with or without cardiac siderosis

Published online by Cambridge University Press:  12 February 2013

A. Alp ,
O. Ozdogan ,
C.C. Guloglu ,
M. Turker  and
B. Atabay
A. Alp*
Affiliation:
Department of Internal Medicine, Tepecik Training and Research Hospital, Yenisehir, Izmir, Turkey
O. Ozdogan
Affiliation:
Department of Cardiology, Tepecik Training and Research Hospital, Yenisehir, Izmir, Turkey
C.C. Guloglu
Affiliation:
Department of Internal Medicine, Tepecik Training and Research Hospital, Yenisehir, Izmir, Turkey
M. Turker
Affiliation:
Department of Pediatric Hematology, Tepecik Training and Research Hospital, Yenisehir, Izmir, Turkey
B. Atabay
Affiliation:
Department of Pediatric Hematology, Tepecik Training and Research Hospital, Yenisehir, Izmir, Turkey
*
Correspondence to: Dr A. Alp, Adnan Menderes University Medical Faculty Hospital, Division of Nephrology, 09000 Aydin, Turkey. Tel: +90 256 444 1 256/2020; Fax: +90 256 214 4086; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives

Iron cardiomyopathy remains the major cause of death in β-thalassaemia major. Excessive iron loading could lead to cardiac dysfunction and arrhythmias. Reduced heart rate variability is associated with a higher risk of arrhythmia and sudden death after myocardial infarction and heart failure. Previous data have reported on reduced heart rate variability in patients with marked cardiac iron accumulation. In this study, we compared heart rate variability among β-thalassaemia major (TM) patients with or without cardiac siderosis.

Methods

Out of 70 β-thalassaemia major patients with preserved ejection fractions, 38 patients with cardiac T2* magnetic resonance imaging assessment were included in our study. Time domain heart rate variability parameters were analysed from 24-hour recorded electrocardiograms and were compared with the control group.

Results

The mean T2* magnetic resonance imaging value was 22.9 ± 13.3 (4.7–47.5). In 21 patients with β-thalassaemia major, the T2* magnetic resonance imaging values were greater than 20 ms and these patients were considered to be in the early stage of the disease. When we compare these patients with control subjects, the standard deviation of all NN intervals was still significantly lower (133.0 ± 32.2 versus 162.8 ± 32.9, p = 0.001) in β-thalassaemia major patients despite normal T2* magnetic resonance imaging values. On the contrary, the standard deviation of all NN intervals was not correlated with haemoglobin levels in these patients (p > 0.05).

Conclusions

Heart rate variability parameters were reduced even in β-thalassaemia major patients without evident cardiac siderosis, as specified by magnetic resonance imaging data. The results of this study show that reduction of heart rate variability may start before cardiac iron loading is demonstrated by T2* magnetic resonance imaging in β-thalassaemia major.

Keywords

β-Thalassaemia majorcardiac magnetic resonance imagingheart rate variability
Type
Original Articles
Information
Cardiology in the Young , Volume 24 , Issue 2 , April 2014 , pp. 263 - 267
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Olivieri, NF. The beta-thalassemias. N Engl J Med 1999; 341: 99–109.CrossRefGoogle ScholarPubMed
2. Wood, JC. Diagnosis and management of transfusion iron overload: the role of imaging. Am J Hematol 2007; 82: 1132–1135.Google Scholar
3. Modell, B, Khan, M, Darlison, M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355: 2051–2052.Google Scholar
4. Borgna-Pignatti, C, Rugolotto, S, De Stefano, P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187–1193.Google Scholar
5. Ehlers, KH, Levin, AR, Markenson, AL, et al. Longitudinal study of cardiac function in thalassemia major. Ann N Y Acad Sci 1980; 344: 397–404.CrossRefGoogle ScholarPubMed
6. Olivieri, NF, Nathan, DG, MacMillan, JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331: 574–578.Google Scholar
7. Meloni, A, Positano, V, Pepe, A, et al. Preferential patterns of myocardial iron overload by multislice multiecho T2* CMR in thalassemia major patients. Magn Reson Med 2010; 64: 211–219.Google Scholar
8. Anderson, LJ, Holden, S, Davis, B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171–2179.Google Scholar
9. Smilde, TD, van Veldhuisen, DJ, van den Berg, MP. Prognostic value of heart rate variability and ventricular arrhythmias during 13-year follow-up in patients with mild to moderate heart failure. Clin Res Cardiol 2009; 98: 233–239.Google Scholar
10. Rutjanaprom, W, Kanlop, N, Charoenkwan, P, et al. Heart rate variability in beta-thalassemia patients. Eur J Haematol 2009; 83: 483–489.Google Scholar
11. Lang, RM, Bierig, M, Devereux, RB, et al. Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440–1463.Google Scholar
12. Schiller, NB, Shah, PM, Crawford, M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358–367.Google Scholar
13. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1996; 17: 354–381.Google Scholar
14. Borgna-Pignatti, C, Rugolotto, S, De Stefano, P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187–1193.Google ScholarPubMed
15. Hamaad, A, Lip, GY, MacFadyen, RJ. Heart rate variability estimates of autonomic tone: relationship to mapping pathological and procedural stress responses in coronary disease. Ann Med 2004; 36: 448–461.Google Scholar
16. Odemuyiwa, O, Malik, M, Farrell, T, Bashir, Y, Poloniecki, J, Camm, J. Comparison of the predictive characteristics of heart rate variability index and left ventricular ejection fraction for all-cause mortality, arrhythmic events and sudden death after acute myocardial infarction. Am J Cardiol 1991; 68: 434–439.Google Scholar
17. Fetsch, T, Reinhardt, L, Mäkijärvi, M, et al. Heart rate variability in time domain after acute myocardial infarction. Clin Sci (Lond) 1996; 91 (Suppl): 136–140.Google Scholar
18. Franzoni, F, Galetta, F, Di Muro, C, Buti, G, Pentimone, F, Santoro, G. Heart rate variability and ventricular late potentials in beta-thalassemia major. Haematologica 2004; 89: 233–234.Google Scholar
19. De Chiara, B, Crivellaro, W, Sara, R, et al. Early detection of cardiac dysfunction in thalassemic patients by radionuclide angiography and heart rate variability analysis. Eur J Haematol 2005; 74: 517–522.Google Scholar